It’s like stopping a blood pressure medicine and then being surprised that people have more heart attacks afterwards.
It’s like stopping a blood pressure medicine and then being surprised that people have more heart attacks afterwards.
> In this cohort study of adults with overweight or obesity who initiated treatment with injectable semaglutide or tirzepatide and discontinued the index medication between 3 and 12 months after initiation, 19.6% restarted the index medication and 35.2% received an alternative treatment in the year after initial treatment discontinuation. The average weight change 1 year after index medication discontinuation was relatively small; however, there was considerable individual-level variability.
https://dom-pubs.pericles-prod.literatumonline.com/doi/10.11...
I don't know why a study that focuses on discontinuation didn't split the groups that restarted or transitioned against the group that actually just stopped.
Which makes sense since we have strong evidence for the GLP-1s providing significant protective benefit even without weight loss.
GLP-1 masks the problem and people don't realize their actions aren't ideal once the mask is removed.